Mangalam Drugs re-appoints Independent Director for second term

1 min read     Updated on 18 Jun 2026, 07:57 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Mangalam Drugs and Organics Limited announced that shareholders have approved the re-appointment of Shri. Praveen Saxena as an Independent Director for a second term of five consecutive years. The resolution was passed through a postal ballot process with 99.95% of the valid votes cast in favour.

powered bylight_fuzz_icon
43338408

*this image is generated using AI for illustrative purposes only.

Mangalam Drugs and Organics Limited has secured shareholder approval to re-appoint Shri. Praveen Saxena as an Independent Director for a second term of five consecutive years. The resolution was passed via a postal ballot conducted under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with 99.95% of valid votes cast in favour. This outcome ensures the continuity of leadership within the company's governance structure.

The postal ballot notice was sent to members on May 18, 2026, with remote e-voting facilities provided by the National Securities Depository Limited (NSDL). The voting process commenced on May 19, 2026, and concluded on June 17, 2026. Mr. Brijmohan Maheshwari, Proprietor of M/s. BMM and Associates, was appointed as the Scrutinizer to oversee the fairness and transparency of the e-voting process.

Voting Results Summary

The special resolution received overwhelming support across shareholder categories. A total of 4,500,157 votes were polled, representing 28.43% of the outstanding shares. The breakdown of the voting results is as follows:

Category Votes in Favor Votes Against % of Votes in Favor
Promoter and Promoter Group 4,389,031 0 100.00
Public - Institutional shareholders 17,505 0 100.00
Public - Non-Institution shareholders 91,423 2,198 97.65
Total 4,497,959 2,198 99.95

The total number of members eligible to vote as on the record date was 25,235. While the promoter group participated actively with a 77.78% turnout of their holdings, the participation from non-institutional public shareholders was lower at 0.92%. The resolution required a special majority, which was comfortably met with the requisite approval from the members.

Procedural Compliance

The company complied with all regulatory requirements, including public advertisements in the Financial Express and Loksatta on May 19, 2026, to inform members about the ballot. The voting rights were reckoned based on the register of members as on May 15, 2026. The Scrutinizer's report confirmed that the e-voting system was blocked at the end of the voting period, and the votes were unblocked and tabulated in the presence of witnesses on June 17, 2026.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.30%+0.14%+0.71%+22.96%-62.85%-79.29%

What strategic initiatives will Shri. Praveen Saxena prioritize during his second term to drive company growth?

How will the board leverage the overwhelming shareholder support to implement new governance policies?

What impact will this leadership continuity have on investor confidence and stock performance?

Mangalam Drugs & Organics
View Company Insights
View All News
like17
dislike

Mangalam Drugs promoters declare no encumbrance in FY 2025-26

1 min read     Updated on 18 Jun 2026, 04:19 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Promoters of Mangalam Drugs and Organics declared no new encumbrances on shares in FY 2025-26, complying with SEBI regulations. The filing confirms no direct or indirect charges beyond prior disclosures.

powered bylight_fuzz_icon
43282171

*this image is generated using AI for illustrative purposes only.

Promoters of Mangalam Drugs and Organics Limited have confirmed that they did not create any encumbrance on their shares during the financial year 2025-26. This declaration, made on behalf of the promoters and members of the promoter group, ensures that no direct or indirect charges were placed on their holdings other than those already disclosed to the exchanges.

The disclosure was submitted by Shri. Govardhan M. Dhoot, a promoter of the company, to the BSE Ltd and the National Stock Exchange of India. The filing was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates such annual declarations to maintain transparency regarding shareholding patterns.

Key Details of the Filing

Aspect Details
Regulation Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Financial Year 2025-26
Declarant Shri. Govardhan M. Dhoot, Promoter
Encumbrance Status No new encumbrances created

The declaration covers the promoters, members of the promoter group, and persons acting in concert with them. By confirming the absence of new encumbrances, the company provides assurance to shareholders regarding the stability of the promoter's shareholding structure for the specified period.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.30%+0.14%+0.71%+22.96%-62.85%-79.29%

How will the absence of new encumbrances impact investor confidence in Mangalam Drugs and Organics Limited?

What are the expected capital allocation strategies of the promoters given their unencumbered shareholding status?

Could this clean shareholding structure position the company for potential mergers, acquisitions, or strategic partnerships?

Mangalam Drugs & Organics
View Company Insights
View All News
like15
dislike

More News on Mangalam Drugs & Organics

1 Year Returns:-62.85%